<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322294</url>
  </required_header>
  <id_info>
    <org_study_id>14GGHF</org_study_id>
    <nct_id>NCT02322294</nct_id>
  </id_info>
  <brief_title>Investigating the Effects of Glucodia™ on Glucose Parameters, Triglycerides and Body Weight</brief_title>
  <acronym>14GGHF</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Effects of 8 Weeks Use of Glucodia™ on Glucose Parameters, Triglycerides and Body Weight as Compared to Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fuji Oil Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Synergize Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is investigating the effects of 8 weeks of supplementation with Glucodia™, on
      glucose parameters, triglycerides and body weight as compared to a placebo. Half of the
      subjects will be administered Glucodia™, while the other half will receive placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glucose response to 2-hour oral glucose tolerance test (OGTT) in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Assessed by the change in the area under the curve in glucose response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin response to 2-hour oral glucose tolerance test (OGTT) in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Assessed by the change in the area under the curve in insulin response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline, week 4 and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting insulin in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline, week 4 and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline, week 4 and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in adiponectin levels in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline, week 4 and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid panel levels in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline, week 4 and week 8</time_frame>
    <description>Lipid panel includes total cholesterol, triglycerides, HDL, LDL, free fatty acids and non-esterified fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline, week 4 and week 8</time_frame>
    <description>Assessed via DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline, week 4 and week 8</time_frame>
    <description>Assessed via circumference measurements of the arm, thigh, hip and waist and the hip to waist ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline, week 4 and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in appetite in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Baseline, week 4 and week 8</time_frame>
    <description>Assessed using a Satiety VAS scale questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Vital Signs in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Screening, Baseline, week 4, week 8</time_frame>
    <description>Blood Pressure and Heart Rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Blood Hematology and Clinical Chemistry in subjects taking Glucodia™ versus Placebo</measure>
    <time_frame>Screening, Baseline, week 4 and week 8</time_frame>
    <description>CBC, electrolytes, creatinine, AST, ALT, GGT, bilirubin, HbA1c, BUN, total protein, albumin, globulin and calcium</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Glucose Parameters</condition>
  <condition>Triglycerides</condition>
  <condition>Body Weight</condition>
  <arm_group>
    <arm_group_label>Glucodia™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucodia™</intervention_name>
    <arm_group_label>Glucodia™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female adults, aged 21 to 45 years

          -  BMI of 25 kg/m2 to 40 kg/m2 (inclusive)

          -  Subjects with Fasting Plasma Glucose 5.56mmol/L to 6.94mmol/L (100mg/dL-125mg/dL) AND
             EITHER Fasting Insulin 60 pmol/L to 180 pmol/L OR Triglycerides 1.36mmol/L to 3.39
             mmol/L (120mg/dL-300mg/dL)

          -  Subject is not of child bearing potential. Defined as females who have had a
             hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural
             or surgically with &gt; 1 year since last menstruation).

        OR Female subject of childbearing potential must agree to use a medically approved method
        of birth control and have a negative urine pregnancy test result. Acceptable methods of
        birth control include: Hormonal contraceptives including oral contraceptives, hormone birth
        control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable
        contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System),
        Double-barrier method (condoms with spermicide or diaphragm with spermacide), Non-hormonal
        intrauterine devices, Vasectomy of partner, Non-heterosexual lifestyle

          -  Subjects who have no plans to change their smoking habits during the trial period.

          -  Subjects who are normally active and are deemed to be healthy by the Medical Director

          -  Subjects who agree to maintain their current level of activity throughout the trial
             period.

          -  Subjects who agree to maintain their current dietary habits throughout the trial
             period.

          -  Subjects who have given voluntary, written, informed consent to participate in the
             study.

        Exclusion Criteria:

          -  Subjects who are pregnant, breastfeeding or planning on becoming pregnant throughout
             the course of the study.

          -  Subjects with Fasting Glucose &lt; 5.56 mmol/L or &gt; 6.94 mmol/L

          -  Subjects with Fasting Plasma Glucose 5.56 mmol/L to 6.94 mmol/L who DO NOT have EITHER
             Fasting Insulin 60 pmol/L to 180 pmol/L OR Triglycerides 1.35 mmol/L to 3.39 mmol/L

          -  Subjects with BMI &lt; 25 kg/m2 or &gt; 40 kg/m2

          -  Subjects who have experienced weight loss or gain of greater than 4.5 kg
             (approximately 10 lbs) in the past 3 months

          -  Subjects with uncontrolled hypertension ( ≥ 140 mmHg)

          -  Subjects with any major diseases of the cardiovascular, renal, hepatic,
             gastrointestinal, pulmonary or endocrine systems

          -  History of or current diagnosis of any cancer (except for successfully treated basal
             cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer
             in full remission more than 5 years after diagnosis are acceptable

          -  Subjects with neurological disorders or significant psychiatric illnesses

          -  Subjects with unstable thyroid disease

          -  Subjects who are immuno-compromised (HIV positive, on anti-rejection medication,
             rheumatoid arthritis)

          -  Subjects who have taken any medication or natural health products intended for the
             management of diabetes, dyslipidemia or body weight within 3 months of randomization.

          -  Subjects who use illicit drugs or have a history of alcohol or drug abuse within the
             past 6 months

          -  Subjects who currently consume greater than 2 standard alcoholic drinks per day.

          -  Subjects who have participated in a clinical research trial within 30 days prior to
             randomization.

          -  Subjects with an allergy or sensitivity to the investigational product ingredient.

          -  Subjects who are cognitively impaired and/or who are unable to give informed consent

          -  Subjects who have abnormal laboratory results or any other medical or psychological
             condition which, in the opinion of the Principle Investigator, may adversely affect
             the subjects ability to complete the study or its measures or which may pose
             significant risk to the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>June 8, 2016</last_update_submitted>
  <last_update_submitted_qc>June 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Protein</keyword>
  <keyword>mung bean</keyword>
  <keyword>glucose</keyword>
  <keyword>triglycerides</keyword>
  <keyword>insulin</keyword>
  <keyword>body weight,</keyword>
  <keyword>DXA scan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

